BTTX (Better Therapeutics) Notes Receivable: $0.00 Mil (As of Sep. 2023)


What is Better Therapeutics Notes Receivable?

Better Therapeutics BTTX Notes Receivable is $0.00 Mil as of Sep. 2023.

Better Therapeutics's Notes Receivable for the quarter that ended in Sep. 2023 was $0.00 Mil.

Better Therapeutics Notes Receivable Related Terms

Better Therapeutics Notes Receivable Historical Data

* Premium members only.

The historical data trend for Better Therapeutics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Better Therapeutics Notes Receivable Chart

Better Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Notes Receivable
0.00 0.00 0.00 0.00

Better Therapeutics Quarterly Data
Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Better Therapeutics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Better Therapeutics (BTTX) has a Notes Receivable of $0.00 Mil as of Sep. 2023. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Better Therapeutics and its competitors.
Is Better Therapeutics' Notes Receivable too high?
Better Therapeutics' current Notes Receivable is $0.00 Mil.
How does Better Therapeutics' Notes Receivable compare to CYCN and CELZ?
Better Therapeutics' Notes Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Better Therapeutics and its competitors. Better Therapeutics's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Better Therapeutics stock overvalued right now?
Better Therapeutics (BTTX) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Better Therapeutics (BTTX), the current Notes Receivable is $0.00 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Better Therapeutics Business Description

Address 548 Market Street, Suite 49404, San Francisco, CA, USA, 94104
Better Therapeutics Inc is a prescription digital therapeutics company developing a novel form of cognitive behavioural therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions.